Trials / Active Not Recruiting
Active Not RecruitingNCT05964257
To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy
A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy.
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 188 (actual)
- Sponsor
- Huons Biopharma · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A double-blind, randomized, placebo-controlled, multi-center, phase III study to evaluate the efficacy and safety of LIZTOX in subjects with benign Masseteric hypertrophy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum toxin type A | Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2. |
| DRUG | normal Saline | Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2. |
Timeline
- Start date
- 2023-07-25
- Primary completion
- 2024-03-07
- Completion
- 2025-05-30
- First posted
- 2023-07-27
- Last updated
- 2024-09-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05964257. Inclusion in this directory is not an endorsement.